Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telavancin - Cumberland Pharmaceuticals

Drug Profile

Telavancin - Cumberland Pharmaceuticals

Alternative Names: Arbelic; TD-6424; Telavancin hydrochloride; Vibativ

Latest Information Update: 18 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Theravance; Theravance Biopharma
  • Developer Clinigen; Cumberland Pharmaceuticals; Innoviva; MEGAPharma; PENDOPHARM; Theravance Biopharma; University of Illinois at Chicago
  • Class Aminoglycosides; Glycopeptides; Lipopeptides; Peptide antibiotics
  • Mechanism of Action Cell membrane permeability enhancers; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Skin and soft tissue infections

Highest Development Phases

  • Marketed Bacteraemia; Nosocomial pneumonia; Skin and soft tissue infections
  • Phase III Osteomyelitis
  • No development reported Bacterial infections; Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 18 Oct 2019 Efficacy and adverse events data from a phase III ATTAIN trial in Nosocomial pneumonia released by Cumberland Pharmaceuticals
  • 28 May 2019 No recent reports of development identified for phase-I development in Bacterial-infections(In volunteers) in USA (IV, Infusion)
  • 31 Dec 2018 Cumberland Pharmaceuticals and MegaPharma enter into an agreement for the commercialisation of telavancin, in Israel and Palestine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top